Jiangsu Hengrui Pharmaceuticals and Kailera Therapeutics report positive topline data from 8 mg dose of phase 2 obesity trial of GLP-1/GIP receptor dual agonist HRS9531
"Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial." Lancet
GLP-1 receptor agonists are generally considered safe and effective when prescribed appropriately
It is possible in some circumstances
These drugs slow gastric emptying, increase feelings of fullness, and reduce hunger signals to the brain
Benefits Semaglutide and liraglutide share a few common benefits, such as: Both drugs promote blood sugar control in patients with type 2 diabetes Semaglutide (Wegovy) and liraglutide (Saxenda) help reduce body weight in obese and overweight patients Both drugs have potential cardiovascular benefits and reduce the risk of heart attack, stroke, and cardiovascular death Side effects As semaglutide and liraglutide belong to the same class of drugs (GLP-1 receptor agonist), they have common side effects such as nausea, vomiting, diarrhea, constipation, stomach pain, injection site reaction, and pancreatitis
